WU, LIANG

Release date:2016-05-25  Release:

  

WU, LIANG

Associate Professor of Pharmacology

Jiangsu Key Laboratory of Drug Screening

Phone: 86-25-83271099

Email: 1020132373@cpu.edu.cn

Research Summary

Professor WU’s research focuses on Cancer Immunology and targeted drug development. He has been doing research on the effect of IL-21 on EBV positive DLBCL. Targeted drug development against cancer is his research interest as well. He is currentlydeveloping small molecules to restore the function of P53 in cancer cells.


Education

2013       Ph.D., Cancer Immunology, karolinska Institutet

2007      M.S., Molecular cell BiologyUppsala University

1993       B.S.,   Biotechnology, Nanjing Normal University

Academic Experience

2016-      Associate Professor of Pharmacology, Jiangsu Key Laboratory of Drug Screening

2013-2015  Senior Research Scientist of PharmacologyJiangsu Key Laboratory of Drug Screening

Publications

Epstein-Barr virus infection. Immunology. 127(4): 549-57, 2009.

Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells. J Virol. 86(8): 4701-7, 2012.

Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma. Cytokine. 57(3): 360-71, 2012.

EBV counteracts IL-21-induced apoptosis in an EBV-positive diffuse large B-cell lymphoma cell line. Int J Cancer. 133(3): 766-70, 2013.